ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the use of its “at the market” equity offering plan.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement a “at the market” equity offering program under which Acasti may issue as well as promote from time to time the common shares of its having an aggregate offering price of up to $75 million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions reported on January 27, 2021, Acasti issued an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares were sold at prevailing market rates averaging US$1.0747 per share. No securities were offered in the facilities of the TSXV or perhaps, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with their services. As a result of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and can supply the Company with extra freedom in its continuous review process to check out as well as evaluate strategic options.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescription drugs using OM3 greasy acids delivered both as totally free fatty acids and bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have extensive clinical proof of safety as well as efficacy for lowering triglycerides in people with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for individuals with serious HTG.
Forward Looking Statements – ACST Stock
Statements of this press release that aren’t statements of historical or current truth constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking assertions involve known and unknown risks, uncertainties, along with other unknown factors that may result in the particular outcomes of Acasti to be materially different from historical results or from any future outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, readers are actually urged to look at statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be forward-looking and uncertain. Readers are actually cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this particular press release. Forward-looking statements in this press release include, but aren’t limited to, information or statements concerning Acasti’s strategy, future operations as well as its review of strategic options.
The forward looking statements contained in this specific press release are expressly qualified in their entirety by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” section found in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor aisle of Acasti’s site at www.acastipharma.com. All forward looking statements in that press release are available as of the day of this press release.
ACST Stock – Acasti does not undertake to upgrade any such forward-looking statements whether as a result of information that is brand new , future events or otherwise, except as needed by law. The forward-looking statements contained herein are also subject typically to risks and assumptions as well as uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, including Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the use